Cointime

EnBiotix

company

About

EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.

  • Cambridge,Massachusetts,United States
  • 1 - 10

Highlights

Total Funding Amount
$17.61M
Funding Rounds
5
Investors
5
Acquisition
1
Employee Profiles
3

Details

Last Funding Type
Convertable Note
Last Funding Money Raised
$11M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2012
Number Of Employee
1 - 10
Operating Status
Active

EnBiotix is a product-focused bioengineering company that advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections. Through breakthrough systems and synthetic biology platforms, EnBiotix is transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant bacterial infections. These approaches have developed a robust clinical product pipeline addressing a wide range of acute and chronic infections in what is today over a $40 billion market, with the potential to significantly impact the lives of patients, caregivers, and payors worldwide.

It was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
5
$17.61M
EnBiotix has raised a total of $17.61M in funding over 2 rounds. Their latest funding was raised on Apr 5, 2022 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 5, 2022 Series Unknown $3.46M — — — Detail
Dec 29, 2021 Convertable Note $11M 3 Vectura Group — Detail
Sep 26, 2019 Series Unknown $3.14M — — — Detail
May 12, 2016 Series A — 2 Wired Holdings — Detail
Jan 1, 2016 Grant — — — — Detail

Investors

Number of Lead Investors
Number of Investors
2
5
EnBiotix is funded by 5 investors. Vectura Group and Wired Holdings are the most recent investors.
Investor Name Lead Investor Funding Round
Vectura Group Yes Convertable Note
Wired Holdings Yes Series A
Sanford Biosciences — Convertable Note
Cystic Fibrosis Foundation — Convertable Note
Apeiron Holdings Limited — Series A

Employee Profiles

Number of Employee Profiles
3
EnBiotix has 3 current employee profiles, including Employee Jeffrey D. Wager
Jeffrey D. Wager
Employee
James Collins
Executive

Acquisition

EnBiotix has acquired 1 organizations. Their most recent acquisition was AMP Therapeutics - Antimicrobial Peptides on Nov 3, 2016. They acquired AMP Therapeutics - Antimicrobial Peptides for 0.

Date Company Name
Industry Acquisition Type Price
Nov 3, 2016 AMP Therapeutics - Antimicrobial Peptides
Alternative Medicine acquisition — Detail
Cointime
Content
Company